Abstract
Introduction
Upadacitinib, an oral selective Janus kinase (JAK) inhibitor, is used to treat moderate-to-severe atopic dermatitis (AD). Acne is the most common treatment-emergent adverse event in patients with AD treated with upadacitinib. In this post hoc analysis, we describe the acne events in Japanese patients with AD who received upadacitinib during the Rising Up study.
Methods
In this phase 3, double-blind, 3-year trial evaluating the safety and efficacy of upadacitinib 15 mg or 30 mg in Japanese patients with moderate-to-severe AD, patients were randomized 1:1:1 to receive upadacitinib 15 mg, 30 mg, or placebo for up to 16 weeks. At week 16, placebo-treated patients were re-randomized 1:1 to receive upadacitinib 15 mg or 30 mg. The incidence, characteristics, and management of treatment-emergent acne events up to the 52-week cutoff date were summarized.
Results
Among 272 patients in this analysis, the incidence of acne was higher in patients receiving upadacitinib compared with patients who received placebo. The rate of acne was higher in patients receiving upadacitinib 30 mg (32.4%) compared with those taking upadacitinib 15 mg (17.3%) during the long-term treatment period. All cases of acne were mild or moderate; no cases led to study drug discontinuation. The mean (range) of acne onset was 135.4 (7–465) days after starting study drug. Most acne occurred on the face; inflammatory papules were the most common morphology. Risk factors for acne included relevant concomitant medications (e.g., corticosteroids) started before acne onset and family and personal history of acne. Acne was generally managed with topical treatments.
Conclusion
Mild or moderate acne reported in Japanese patients with AD receiving upadacitinib occurred in a dose-dependent manner and had a variable onset time. Acne was readily managed with topical treatments. Patients and clinicians should be aware of the risk of acne associated with upadacitinib treatment for AD.
Trial Registration
ClinicalTrials.gov identifier, NCT03661138.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Why carry out this study? |
Acne was the most common treatment-emergent adverse event as reported in the primary upadacitinib trials in patients with moderate-to-severe atopic dermatitis. |
This study evaluated the incidence, possible associated medications, clinical characteristics, and management of acne events in Japanese patients with moderate-to-severe atopic dermatitis who were receiving upadacitinib in the first year of the Rising Up study. |
What was learned from this study? |
Approximately 17–32% of Japanese patients with atopic dermatitis treated with upadacitinib experienced acne events that were mild or moderate, had a mean (range) onset time of 135.4 (7–465) days after initiation of therapy, lasted 3–4 months on average, and were readily managed with topical treatments. |
Patients and clinicians should be aware that acne is a potential side effect associated with upadacitinib treatment for atopic dermatitis; however, no special precautionary measures for potential acne development are needed before starting upadacitinib. |
Introduction
Atopic dermatitis (AD) is a chronic, itchy skin disease characterized by inflammation and eczematous morphology [1, 2]. Skin inflammation and symptoms in AD are driven by epidermal skin barrier dysfunction, environmental factors, changes in the skin microbiota, and T lymphocyte infiltration in affected areas [3]. Common treatment options for AD include topical therapies, phototherapy, and systemic or topical immunosuppressants [3]. Recently developed AD treatments include biologic therapies and small-molecule inhibitors targeting cytokines and intracellular signaling molecules related to AD pathology. [4] Multiple cytokines—including interleukin (IL)-4, IL-13, and IL-31—contribute to inflammation and symptoms in AD by signaling via cell surface receptors coupled to cytoplasmic Janus kinases (JAKs) [3]. IL-31 produced by T cells in affected skin also signal to sensory neurons via JAK signaling, leading to the sensation of itchy skin [5]. Together, the relevance of JAK signaling in AD suggests that JAK inhibition is a promising therapeutic strategy to treat the underlying pathophysiology and symptoms of chronic, itchy, eczematous skin in patients with AD.
Upadacitinib is an orally administered, selective, small-molecule JAK inhibitor with greater potency for JAK1 than JAK2, JAK3, or tyrosine kinase 2 [6, 7]. Upadacitinib is approved in Japan, Europe, and the USA for the treatment of moderate-to-severe AD in adolescents and adults [8, 9]. Acne was reported as one of the most common treatment-emergent adverse events in phase 3 placebo-controlled trials of upadacitinib in patients with moderate-to-severe AD (Measure Up 1, NCT03569293; Measure Up 2, NCT03607422; and AD Up, NCT03568318) [1, 2, 10]. In an integrated analysis of these three phase 3 studies up to 16 weeks of follow-up, the incidence of acne was 9.8% with upadacitinib 15 mg, 15.2% with upadacitinib 30 mg, and 2.2% with placebo [11]. Although acne was also reported with upadacitinib treatment in clinical trials for other indications, acne incidence was lower (≤ 7%) than that observed in the AD studies [12]. Despite studies characterizing the incidence of acne associated with upadacitinib treatment in patients with AD [11], little is known about the severity, clinical characteristics, and effective management of acne with upadacitinib treatment in global patient populations including Japanese patients.
Here, we report the incidence, severity, duration, clinical features including possible associated medications, and management of treatment-emergent acne events associated with upadacitinib therapy in Japanese patients who had moderate-to-severe AD during the first year of treatment in the phase 3 Rising Up study.
Methods
Patients
Eligible patients were adolescents (aged 12 to younger than 18 years, body weight ≥ 40 kg) and adults (aged 18–75 years) in Japan who had moderate-to-severe AD [Eczema Area and Severity Index score ≥ 16, validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score ≥ 3, AD affecting at least 10% of body surface area (BSA), and weekly average of daily Worst Pruritis Numerical Rating Scale score of ≥ 4] with symptoms for at least 3 years or longer per Hanifin and Rajka criteria [13] and were candidates for systemic therapy. Excluded patients had previous exposure to JAK inhibitors or dupilumab, had AD lesions on at least 30% of BSA that could not be safely treated with topical corticosteroids (TCS), were unable or unwilling to discontinue current AD treatments, and/or required prohibited medications during the study.
Study Design and Treatment
Rising Up (NCT03661138) was a phase 3, randomized, multicenter, double-blinded study conducted at 43 sites in Japan to evaluate the safety and efficacy of upadacitinib for the treatment of moderate-to-severe AD [14]. The study consisted of a 35-day screening period; a 16-week placebo-controlled, double-blind treatment period; a 36-week blinded extension period (from week 16 to week 52 of treatment); and an open-label extension period (from week 52 to week 160 of treatment), followed by a 30-day follow-up period.
Patients were randomized 1:1:1 to orally receive upadacitinib 15 mg once daily, upadacitinib 30 mg once daily, or placebo (all in combination with concomitant TCS) at baseline of the double-blind treatment period. At the end of 16 weeks, patients who received placebo were re-randomized 1:1 to either upadacitinib 15 mg or upadacitinib 30 mg. After week 16, the use of any concomitant topical medication for AD was optional per investigator discretion. Randomization occurred using an interactive response technology system and a randomization schedule generated by statisticians at AbbVie. Randomization at baseline was stratified by AD severity [moderate (vIGA-AD = 3) versus severe (vIGA-AD = 4)] and by age (< 18 vs 18–40 versus > 40 years); re-randomization at week 16 was stratified by clinical response (“yes” versus “no” achievement of 50% improvement in Eczema Area and Severity Index) and by age.
The Rising Up study was conducted in accordance with Good Clinical Practice Guidelines as defined by the International Conference on Harmonisation and the Declaration of Helsinki. Before participating in the study, all adult patients and parents or legal guardians of adolescent patients provided written informed consent. Independent institutional review boards at each study site reviewed and approved the protocol and informed consent forms before patients were enrolled and treated.
Assessments
Our post hoc analysis assessed the incidence, severity, duration, clinical characteristics, and management of treatment-emergent acne events from baseline (17 November 2018) to week 16 and up to the 52-week cutoff date (18 June 2020).
Acne severity was evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Mild acne (grade 1) was defined as papules and/or pustules covering less than 10% BSA, which may or may not be associated with symptoms of pruritus or tenderness. Moderate acne (grade 2) was defined as papules and/or pustules covering 10–30% BSA, which may or may not be associated with symptoms of pruritus or tenderness but having psychosocial impact and limiting instrumental activities of daily living, or papules and/or pustules covering more than 30% BSA with or without mild symptoms. Severe acne (grade 3) was defined as papules and/or pustules covering more than 30% BSA with moderate-to-severe symptoms that limit self-care activities of daily living and are associated with local superinfection with oral antibiotics indicated. For each reported acne event, relevant information was collected using a supplemental case report form completed by investigators. The time of onset, duration, severity, location/distribution, morphology, and recurrence of treatment-emergent acne events were recorded. Medications used to manage acne events were also recorded. Descriptive data for all patients randomized at baseline of the double-blind treatment period and who received at least one dose of study drug and all observed cases of acne were reported.
Results
Patients
A total of 272 patients were enrolled and randomly assigned at baseline to receive either upadacitinib 15 mg plus TCS (n = 91), upadacitinib 30 mg plus TCS (n = 91), or placebo plus TCS (n = 90). At week 16, 87 placebo-treated patients were re-randomized to receive upadacitinib 15 mg (n = 42) or upadacitinib 30 mg (n = 45). Including those patients who received placebo and switched to upadacitinib, a total of 133 patients received upadacitinib 15 mg and 136 patients received upadacitinib 30 mg. Eight (2.9%) patients discontinued treatment during the first 16 weeks and 16 (6.1%) patients receiving upadacitinib discontinued treatment in the blinded-extension period up to the 52-week cutoff date.
The baseline demographics and characteristics were well balanced across treatment groups (Table 1). The overall mean [standard deviation (SD)] age was 35.6 (12.8) years (13–66 years), 22.4% were female, and 100% were Asians residing in Japan at the time of enrollment in the study. The mean (SD) duration of AD since diagnosis was 22.8 (14.3) years (0.03–51.9 years).
Acne Events
Placebo-Controlled Period Up to Week 16
During the first 16 weeks of treatment, acne was experienced by 13.2% of patients treated with upadacitinib 15 mg, 19.8% of patients treated with upadacitinib 30 mg, and 5.6% of patients receiving placebo (Table 2). Baseline demographics among patients who experienced acne events during the placebo-controlled period are reported in Supplementary Table 1. The mean (SD) age of patients experiencing acne was 28.8 (10.5) years. All acne cases were mild or moderate in intensity and none led to discontinuation of the study drug. Higher rates of acne were reported among female patients than male patients in the upadacitinib 30 mg group, but not in the upadacitinib 15 mg group.
Adults aged 18 to younger than 30 years generally had the highest incidence of acne, followed by adolescents aged younger than 18 years, then adults aged 30 to younger than 65 years (Table 2). Among patients in the placebo group, the incidence of acne was highest in adolescents aged younger than 18 years. No adults aged 65 years or older reported acne events; however, there were limited numbers of patients enrolled in this age group. Most patients treated with upadacitinib experienced events of facial acne, followed by acne on the trunk and/or extremities (Table 3). The most common morphology for acne was inflammatory papules, pustules, and comedones.
Long-Term Treatment Up to Week 52 Cutoff Date
Acne was experienced by 17.3% of patients receiving upadacitinib 15 mg and 32.4% of patients receiving upadacitinib 30 mg up to the week 52 cutoff date (Table 4). Baseline demographics among patients who experienced acne events through the week 52 cutoff date are reported in Supplementary Table 2. The mean (SD) age of patients experiencing acne was 31.2 (11.6) years. All acne cases were mild or moderate in intensity and nonserious; no cases of acne led to discontinuation of the study drug. Similar to the first 16 weeks of treatment, through the week 52 cutoff date, rates of acne were higher in female patients receiving upadacitinib 30 mg than in male patients, most acne events occurred on the face, and the most common morphology was inflammatory papules.
Among all patients who experienced acne during the study, the average time to onset (SD, range) of the first acne event (in days) was similar in patients treated with upadacitinib 15 mg [137.9 (138.0, 7–465) days] compared with upadacitinib 30 mg [134.1 (101.3, 11–364) days]. The first acne event lasted an average (SD, range) of 128.8 (133.9, 20–406) days in the upadacitinib 15 mg group and 106.6 (80.9, 8–307) days in the upadacitinib 30 mg group. Six (4.5%) patients treated with upadacitinib 15 mg and 2 (1.5%) patients treated with upadacitinib 30 mg experienced multiple acne events. Among patients who were randomized to receive upadacitinib at baseline, longitudinal evaluation of patients who experienced acne events demonstrated variable onset time within the study period (Fig. 1).
Most patients who experienced acne events had their acne clinically managed with topical medications (82.6% and 77.3% of patients in the upadacitinib 15 mg and 30 mg groups, respectively), such as anti-infectives (Table 5). Approximately 21% of the patients with acne events were treated with oral medications (e.g., macrolides, tetracyclines) in both upadacitinib treatment groups. No medical treatment was given to manage the acne events in 13.0% of patients receiving upadacitinib 15 mg and 15.9% of patients receiving upadacitinib 30 mg. Of the 80 acne events that began by the week 52 cutoff date, 41.3% (n = 33) had resolved as of the cutoff date.
Among those patients who developed acne while taking upadacitinib, the most common predisposing risk factors (in the upadacitinib 15 mg and upadacitinib 30 mg groups, respectively) were the use of concomitant medications associated with acne (87.0%, 84.1%), family history of acne (30.4%, 27.3%), and a medical history of acne (30.4%, 25.0%). Examples of concomitant medications used by patients who experienced acne and thought to contribute to acne onset included topical corticosteroids, heparinoid cream, white petrolatum, tacrolimus ointment, and adapalene.
Discussion
Upadacitinib therapy was associated with an increased risk of acne in Japanese patients with AD who were enrolled in the Rising Up study. Less than 20.0% of patients treated with upadacitinib 15 mg and about one-third of patients treated with upadacitinib 30 mg reported acne events that occurred at various times with long-term treatment of upadacitinib. The results in this Japanese study were similar to findings in other phase 3 AD clinical trials of upadacitinib [2, 11], which supports a dose-dependent association between upadacitinib and acne development. Importantly, all events of acne in upadacitinib-treated patients were mild or moderate in severity, nonserious, and did not result in discontinuation of upadacitinib treatment.
No clear pattern of time to acne onset was observed. The mean time to onset of the first acne event was over 3 months. In addition, not all acne events started within 1 month of administration (when improvements in skin clearance and pruritus are observed), and many events occurred after 4 months of upadacitinib treatment, which makes it difficult to explain whether these events were directly related to upadacitinib treatment. Most events occurred once and typically lasted for 3–4 months; multiple acne events in individual patients were uncommon. No patient discontinued because of acne and no patient required oral administration of isotretinoin for the treatment of acne. In addition, acne was readily manageable with topical acne treatments such as topical anti-infectives, retinoids, and/or peroxides. Taken together, these findings suggest that acne in upadacitinib-treated patients can be managed per the Japanese acne treatment guidelines for acne vulgaris [15].
Acne prevalence is highest among adolescents and young adults aged 16–20 years and in adult women in the general population [16]. Patients with AD also have a higher prevalence of acne than do individuals observed in the general population [17]. In this study, the incidence of acne observed in adolescent patients is consistent with acne prevalence in the general population and in patients with AD [16, 17]. When compared with patients in trials investigating upadacitinib for rheumatoid arthritis (mean age 55–56 years) [18] or psoriatic arthritis (mean age 53 years) [19], the younger population (mean age 36 years) may partly account for the higher frequency of acne observed in this study. The higher incidence of acne among female patients of all ages treated with upadacitinib 30 mg is consistent with findings that acne is generally more common among female patients with AD compared with male patients [17]; overall, acne severity was similar for male and female patients in this study.
The most common risk factor for developing acne was the use of concomitant medications that have previously been associated with acnegenic potential. Topical corticosteroids, which were required for all patients from baseline through week 16 and optional per investigator discretion after week 16, have been associated with the development of steroid acne [20]. White petrolatum, a common ingredient in topical medications and cosmetics, has moderate comedogenicity that can lead to acne [21]. Tacrolimus cream is also formulated with wax and white petrolatum, which may contribute to acne development [22]. Further research is required to determine the underlying causes of acne in patients treated with both upadacitinib and other concomitant medications with known comedogenic potential.
Acne has also been reported with other systemic (abrocitinib and baricitinib) and topical (delgocitinib) JAK inhibitors approved for the treatment of AD in Japan. Abrocitinib is associated with an acne incidence rate of 2–5% of patients based on an integrated analysis of six studies in predominantly White and Asian patients with AD [23]. Baricitinib is associated with acne incidence rates of 5–15% in Japanese patients with AD who received up to 105 weeks of treatment [24]. In a 52-week open-label study of topical 0.5% delgocitinib ointment in Japanese patients with AD, acne was reported in 4.8% of patients [25]. Overall, little is known about the mechanism leading to different rates of acne events with upadacitinib compared with other systemic and topical JAK inhibitors in patients with AD.
The underlying pathogenesis for upadacitinib-associated acne in patients with AD is not currently understood. AD is characterized by secretion of inflammatory cytokines, activation of JAK signaling, and T-cell infiltration [3]. In addition, JAK1 and JAK3 mRNA levels are increased in inflammatory acne lesions, but not in non-lesional skin [26]. JAK inhibition is thought to reduce JAK activation and inflammation in patients with AD resulting in lower risk of acne development, which is not observed in the upadacitinib AD studies. Further research into the mechanism underlying acne development in JAK inhibitor-treated patients is warranted.
A limitation of this study is the small patient sample size, especially for adolescents, which makes it difficult to predict patients who may be at a higher risk of developing acne with upadacitinib treatment. The results for Japanese patients may not be generalizable to other global populations. Finally, this study did not include a head-to-head comparison with other JAK inhibitors for AD treatments.
Conclusion
Overall, although acne is one of the most common treatment-emergent adverse events seen with upadacitinib treatment in adolescents and adults with moderate-to-severe AD, the events are readily manageable with standard acne treatment. Physicians and patients should be aware that acne may occur with upadacitinib treatment; however, most physicians considering upadacitinib for the treatment of AD are likely to have experience with acne management, so no precautionary measures are necessary. The mechanism behind JAK inhibitor-associated acne requires further research.
References
Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397:2151–68.
Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397:2169–81.
Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4:1.
Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21:21–40.
Furue M, Furue M. Interleukin-31 and pruritic skin. J Clin Med. 2021;10:1906.
Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2:23.
Voss J, Graff C, Schwartz A, et al. Pharmacodynamics of a novel Jak1 selective inhibitor in rat arthritis and anemia models and in healthy human subjects. Arthritis Rheumatol. 2013;65:S1015.
Rinvoq® (upadacitinib) [package insert]. AbbVie Inc., October 2022. https://www.rxabbvie.com/pdf/rinvoq_pi.pdf. Accessed 18 Oct 2022.
Rinvoq® Tablets [package insert]. AbbVie GK, August 2021. Accessed 20 Oct 2022.
Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the Measure Up 1 and Measure Up 2 randomized clinical trials. JAMA Dermatol. 2022;158:404–13.
Mendes-Bastos P, Ladizinski B, Guttman-Yassky E, et al. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: a post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials. J Am Acad Dermatol. 2022;87:784–91.
Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113–28.
Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Dermatovener. 1980;60:44–7.
Katoh N, Ohya Y, Murota H, et al. A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): an interim 24-week analysis. JAAD Int. 2022;6:27–36.
Hayashi N, Akamatsu H, Iwatsuki K, et al. Japanese Dermatological Association Guidelines: guidelines for the treatment of acne vulgaris 2017. J Dermatol. 2018;45:898–935.
Tan JK, Bhate K. A global perspective on the epidemiology of acne. Br J Dermatol. 2015;172(Suppl 1):3–12.
Thyssen JP, Nymand LK, Maul JT, et al. Incidence, prevalence and risk of acne in adolescent and adult patients with atopic dermatitis: a matched cohort study. J Eur Acad Dermatol Venereol. 2022;36:890–6.
Kameda H, Takeuchi T, Yamaoka K, et al. Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE). Arthritis Res Ther. 2021;23:9.
Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2021;80:312–20.
Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54:1–15 (quiz 16-18).
Kligman AM, Mills OH Jr. Acne cosmetica. Arch Dermatol. 1972;106:843–50.
PROTOPIC® (tacrolimus) ointment [package insert]. Astellas Pharma, November 2011. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050777s018lbl.pdf. Accessed 15 Mar 2023.
Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program. Am J Clin Dermatol. 2021;22:693–707.
Katoh N, Takita Y, Isaka Y, Nishikawa A, Torisu-Itakura H, Saeki H. Pooled safety analysis of baricitinib in adult participants with atopic dermatitis in the Japanese subpopulation from six randomized clinical trials. Dermatol Ther (Heidelb). 2022;12:2765–79.
Nakagawa H, Nemoto O, Igarashi A, et al. Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis. J Dermatol. 2020;47:114–20.
Awad SM, Tawfik YM, El-Mokhtar MA, El-Gazzar AF, Abdel Motaleb AA. Activation of Janus kinase signaling pathway in acne lesions. Dermatol Ther. 2021;34:e14563.
Acknowledgements
AbbVie and authors thank all the trial investigators and patients who participated in this study.
Funding
AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. AbbVie also provided funding for the journal’s Rapid Service Fee.
Medical Writing and Editorial Assistance
Medical writing support was provided by Michael Dyle, PhD, and Callie A S Corsa, PhD, of JB Ashtin, and funded by AbbVie.
Authorship
All named authors meet the International Committee of Medical Journal Editors’ criteria for authorship for this article. All authors had access to relevant data and participated in the drafting, review, and approval of this version to be published. No honoraria or payments were made for authorship.
Author Contributions
All authors critically reviewed this manuscript, contributed to data interpretation, and provided final approval for publication. John Liu contributed to study design. Masanori Ikeda and Takuya Sasaki contributed to data acquisition. Yingyi Liu contributed to statistical analysis.
Prior Presentation
Portions of these data were previously presented at the 38th Annual Meeting of the Japanese Organization of Clinical Dermatologists (JOCD 2022); 23–24 April 2022; Yamashita-cho, Kagoshima, Japan.
Disclosures
Nobukazu Hayashi has received research funding, consultancy fees, and speaker honoraria from AbbVie GK and Maruho, and research funding and speaker honoraria from Sun Pharma Japan Limited. Masanori Ikeda has received a scholarship donation from Central Research Institute of Pias. John Liu, Eliza Raymundo, Yingyi Liu, and Takuya Sasaki are full-time employees of AbbVie Inc., and may hold AbbVie stock and/or stock options. Kenshi Yamasaki has received honoraria as a speaker from AbbVie, Boehringer Ingelheim Japan, Eisai, Eli Lilly Japan, Janssen, Maruho, Novartis, Pola Chemical Industries, Sato Seiyaku, Sun Pharma, Taiho Yakuhin, and UCB Japan.
Compliance with Ethics Guidelines
This study was conducted in accordance with Good Clinical Practice Guidelines as defined by the International Conference on Harmonisation and the Declaration of Helsinki. Before participating in the study, all adult patients and parents or legal guardians of adolescent patients provided written informed consent. Independent institutional review boards at each study site reviewed and approved the protocol and informed consent forms before patients were enrolled and treated.
Data Availability
AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, clinical study reports, or analysis plans), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. These clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal, Statistical Analysis Plan (SAP), and execution of a Data Sharing Agreement (DSA). Data requests can be submitted at any time after approval in the United States and Europe and after acceptance of this manuscript for publication. These data will be accessible for 12 months, with possible extensions considered. For more information on the process or to submit a request, visit the following link: https://www.abbvieclinicaltrials.com/hcp/data-sharing/.html.
Author information
Authors and Affiliations
Corresponding author
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Hayashi, N., Ikeda, M., Liu, J. et al. Acne Among Japanese Patients with Atopic Dermatitis Receiving Upadacitinib in the Phase 3 Rising Up Study. Dermatol Ther (Heidelb) 13, 1817–1830 (2023). https://doi.org/10.1007/s13555-023-00961-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13555-023-00961-9